MedTrace Logo

Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT)

NCT04640181 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-06-30

No results posted yet for this study

Summary

This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in hospitalized subjects with COVID-19.

Conditions

  • Covid19

Interventions

DRUG

Enoxaparin

Subcutaneous enoxaparin While hospitalized only.

DRUG

Rivaroxaban

Oral rivaroxaban While hospitalized and through discharge for a total of 28 days.

Sponsors & Collaborators

  • St. David's HealthCare

    lead OTHER

Principal Investigators

  • Edward Chafizadeh, MD · Cardio Texas, PLLC

  • Theresa Pham, MD · PPD Austin

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-06-28
Completion
2021-06-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04640181 on ClinicalTrials.gov